期刊： EXPERT OPINION ON EMERGING DRUGS, 2023; 28 (4)
IntroductionSignificant advances in migraine research have contributed to the development of new drugs for the treatment of migraine. Monoclonal antib......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2023; 28 (2)
IntroductionThe discovery of therapeutic proteomic targets has resulted in remarkable advances in oncology. Identification of functional and hallmark ......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2023; 28 (2)
IntroductionChronic cough is a debilitating condition that is among the most common reasons for seeking medical attention yet remains challenging to m......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2023; 28 (1)
IntroductionCurrent therapeutic options for patients with ulcerative colitis comprise monoclonal antibodies against tumor necrosis factor (TNF), alpha......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2023; 28 (1)
IntroductionDespite therapeutic advances in the field of diabetes management since the discovery of insulin 100 years ago, there are still unmet clini......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2023; 28 (2)
IntroductionChronic hepatitis delta (CHD) is the most severe form of chronic viral hepatitis. Until recently, its treatment consisted of pegylated int......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2023; 28 (3)
IntroductionSystemic mastocytosis (SM) is a complex and heterogeneous disease, characterized by the clonal accumulation of mast cells in one or more o......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2023; 28 (4)
IntroductionDepression is a common disabling psychiatric disorder, which - in extreme cases - may lead to suicide if untreated or inadequately treated......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2023; ()
IntroductionEndometriosis is an estrogen-dependent disease that gives rise to pelvic pain and infertility. Although estroprogestins and progestins cur......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2023; 28 (1)
IntroductionWhilst the introduction of direct oral anticoagulants (DOACs) has improved the prevention of thromboembolic events, there is still a need ......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2023; 28 (2)
IntroductionLung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) as the most common subtype. In......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2023; 28 (3)
IntroductionDespite the availability of a variety of therapeutic compounds and improved management strategies, one-third of UC patients with moderate-......
期刊： EXPERT OPINION ON EMERGING DRUGS, 2023; 28 (4)
IntroductionCurrently approved drug treatments for idiopathic pulmonary fibrosis (IPF), pirfenidone and nintedanib, have been shown to slow lung funct......
